Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
The DOI matches its Crossref record; 59 of the 63 references it cites were found in a registry or an index.
Abstract
Background The frequency of obesity has risen dramatically in recent years but only few safe and effective drugs are currently available. We assessed the effect of liraglutide on bodyweight and tolerability in obese individuals without type 2 diabetes. Methods We did a double-blind, placebo-controlled 20-week trial, with open-label orlistat comparator in 19 sites in Europe. 564 individuals (18-65 years of age, body-mass index 30-40 kg/m2) were randomly assigned, with a telephone or web-based system, to one of four liraglutide doses (1.2 mg, 1.8 mg, 2.4 mg, or 3.0 mg, n=90-95) or to placebo (n=98) administered once a day subcutaneously, or orlistat (120 mg, n=95) three times a day orally. All individuals had a 500 kcal per day energy-deficit diet and increased their physical activity throughout the trial, including the 2-week run-in. Weight change analysed by intention to treat was the primary endpoint. An 84-week open-label extension followed. This study is registered with ClinicalTrials.gov, number NCT00422058. Findings Participants on liraglutide lost significantly more weight than did those on placebo (p=0.003 for liraglutide 1.2 mg and p Interpretation Liraglutide treatment over 20 weeks is well tolerated, induces weight loss, improves certain obesity-related risk factors, and reduces prediabetes. Funding Novo Nordisk A/S, Bagsvaerd, Denmark.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Naltrexone/bupropion-ER produced placebo-subtracted weight loss of ~4–5% in persons without T2D750–752”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [751]
In the citing paper
“Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is used in the treatment of obesity because it induces weight loss 21-23 and maintains low-calorie diet-induced weight loss for at least 1 year, 11,24 primarily by means of appetite inhibition. 25”
From Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined (2021) · cites this paper as [21]
In the citing paper
“Results from a phase 2 randomized, placebo-controlled trial of liraglutide (1.2–3.0 mg) in 564 obese non-diabetic adults demonstrated that liraglutide 3.0 mg was statistically significantly more effective than orlistat, or diet and exercise alone, at reducing weight over 20 and 52 weeks, and weight loss was dose-dependent.9, 10”
In the citing paper
“A clinical study involving 564 adults (BMI 30-40 kg/m2, without T2DM) found that compared with orlistat (3×120 mg, weight loss of 4.1 kg), LIR (subcutaneous administration of 1.2 mg/d, 1.8 mg/d, 2.4 mg/d or 3 mg/d) had an average weight loss of 4.8-7.2 kg, the two-year extended experiment of which also showed similar results (88, 89).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [89]
In the citing paper
“Liraglutide resulted in 3.4 to 6.1% difference in mean weight loss compared to placebo [10–14, 19].”
From Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review (2022) · cites this paper as [14]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Pickering, T. G., Hall, J. E., Appel, L. J., Falkner, B. E., Graves, J., Hill, M. N., Jones, D. W., Kurtz, T., Sheps, S. G., & Roccella, E. J. (2005) · Circulation · doi:10.1161/01.cir.0000154900.76284.f6 · Cited by 3,985
Follow-up report on the diagnosis of diabetes mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2003) · Diabetes Care · doi:10.2337/diacare.26.11.3160 · Cited by 3,784
Mechanisms linking obesity with cardiovascular disease
Van Gaal, L. F., Mertens, I. L., & De Block, C. E. (2006) · Nature · doi:10.1038/nature05487 · Cited by 2,814
Available, N. (2000) · JAMA · doi:10.1001/jama.284.23.3043 · Cited by 2,344
Pickering, T. G., Hall, J. E., Appel, L. J., Falkner, B. E., Graves, J., Hill, M. N., Jones, D. W., Kurtz, T., Sheps, S. G., & Roccella, E. J. (2005) · Hypertension · doi:10.1161/01.hyp.0000150859.47929.8e · Cited by 2,051
The Atlas of Heart Disease and Stroke
Mackay, J., Mensah, G. A., & Mendis, S. (2004) · Medical Entomology and Zoology · Cited by 1,550
Research works printed but not linked: 2
- 2003, US Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute, JAMA, 289, 2560
- Garber, 2009, Monotherapy with liraglutide, a once-daily human GLP-1 analog, provides sustained reductions in A1c, FPG, and weight compared with glimepiride in type 2 diabetes: LEAD-3 mono 2-year results, Diabetes, 58, A42
Cited by
Moher, D., Hopewell, S., Schulz, K. F., Montori, V., Gotzsche, P. C., Devereaux, P. J., Elbourne, D., Egger, M., & Altman, D. G. (2010) · BMJ · doi:10.1136/bmj.c869 · Cited by 8,883
“’’[176] ExplanationdData can be analysed in many ways, some of which may not be strictly appropriate in a particular situation.”
BackgroundEuropean Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
Prediabetes: a high-risk state for diabetes development
Tabák, A. G., Herder, C., Rathmann, W., Brunner, E. J., & Kivimäki, M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60283-9 · Cited by 2,958
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Self-citationMoher, D., Hopewell, S., Schulz, K. F., Montori, V., Gøtzsche, P. C., Devereaux, P. J., Elbourne, D., Egger, M., & Altman, D. G. (2012) · International Journal of Surgery · doi:10.1016/j.ijsu.2011.10.001 · Cited by 2,345
“We aimed to assess whether data provided evidence of superiority of each liraglutide dose to placebo (primary objective) and to orlistat (secondary objective)’’[176].”
Method
Metadata
- Authors
- Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E.
- Affiliations
- University of Copenhagen (DK)
- Karolinska University Hospital (SE)
- Helsinki University Hospital (FI)
- Kuopio University Hospital (FI)
- Novo Nordisk (Denmark) (DK)
- Glasgow Royal Infirmary (GB)
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2009-11
- Volume
- 374
- Issue
- 9701
- Pages
- 1606-1616
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2152835319
- Cited by
- 1,163
- References
- 63
- Citations by year
- 2026: 36 · 2025: 56 · 2024: 101 · 2023: 75 · 2022: 63 · 2021: 59 · 2020: 42 · 2019: 47 · 2018: 43 · 2017: 54 · 2016: 68 · 2015: 96 · 2014: 90 · 2013: 94 · 2012: 75
- FWCI
- 56.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- liraglutide, obesity, weight loss, GLP-1 receptor agonists, orlistat, body weight, tolerability, adverse events, energy deficit diet, physical activity, dose-response relationship, subcutaneous administration, non-diabetic obesity, open-label extension, weight regain, weight regain prevention, weight loss maintenance
- MeSH terms
- Liraglutide, Orlistat, Analysis of Variance, Dose-Response Relationship, Drug, Double-Blind Method, Europe, Female, Humans, Injections, Subcutaneous, Lactones, Male, Obesity, Prediabetic State, Safety, Weight Loss, Body Mass Index, Logistic Models, Treatment Outcome, Anti-Obesity Agents, Glucagon-Like Peptide 1, Waist Circumference
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. https://app.cochat.ai/papers/10.1016/s0140-6736(09)61375-1
- The paper
- Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009). Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. The Lancet. https://doi.org/10.1016/s0140-6736(09)61375-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.